The World Bank’s joint report with the Chinese government found that, without health care reform, health spending would increase to USD 2.5 trillion in 2035, up from USD 543.5 billion in 2014.

China is one of the largest pharmaceutical markets in the world - and a field of tension between unique to disruptive medical innovations and generic products.

As part of Healthy China 2030, the Chinese government has opted to ramp up pressure on reimbursement negotiations and procurement processes.

Cancer is on the rise in China. In 2014, the country saw 2.3 million deaths from the disease and 3.8 million new cases, accounting for more than one fifth of premature deaths and more than a quarter of new cancer cases worldwide.

In an era with unprecedented longevity and declining birth rates, we are approaching a future defined by more people aged over 60 than under 15 for the first time in human history.

After a year-long debate, the Japanese government is on the cusp of announcing their final decision on the reform of its drug pricing system.

At Bayer Pharmaceuticals, we focus on researching, developing specialty-focused innovative medicines that provide significant clinical benefit and value in areas of high unmet medical need such as cardiology and oncology.

Japan is an aging society and the prevalence of cancer and cardiovascular diseases is increasing.